MediciNova Reports Positive Phase II Results for Asthma
Posted on: Friday, 12 October 2007, 06:00 CDT
Biopharmaceutical company MediciNova has reported positive results from a Phase IIa clinical study of its novel intravenous product candidate for the treatment of acute severe asthma attack.
The randomized, double-blind, placebo controlled, dose-escalation study achieved statistical significance in its primary endpoint of mean change in FEV1 (forced expiratory volume in 1 second) from baseline at 15 minutes (the end of the infusion) at doses of 10, 16, 30 and 60 micrograms/min of novel intravenous asthma product, MN-221 compared to placebo. There were no clinically significant cardiovascular, electrocardiogram, or vital sign changes, nor were there any other safety concerns observed at any dose tested.
Yuichi Iwaki, president and CEO, said: "We are extremely pleased and encouraged by the Phase IIa clinical study results and believe that MN-221 has the potential to become a new standard of care for status asthmaticus.
"The improvements in FEV1 and favorable cardiac safety findings also suggest that MN-221 could be broadly useful in management of asthma and other obstructive lung diseases such as chronic obstructive pulmonary disease. We look forward to further progressing MN-221 through clinical development."
Source: Datamonitor
Related Articles
- Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
- Elixir Pharmaceuticals Initiates Final Phase III Clinical Study Prior to NDA
- Positive Findings From Clinical Studies of QUADRAMET(R) in Prostate Cancer Patients With Metastatic Bone Disease Presented at ASCO Prostate Cancer Symposium
- Coley Pharmaceutical Group Initiates Phase II Clinical Study of Actilon(TM) for Hepatitis C
- U. Enlists Patients in Clinical Study Linked to Fatal Lung Disease
- Australian Cancer Technology Provides Update on Ongoing Clinical Study of Pentrys Vaccine for Prostate Cancer
- Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers
- Bioaccelerate's Development Partner AustCancer Commences Phase II Clinical Study of RP101 for Metastatic Pancreatic Cancer
- AustCancer Commences Phase II Clinical Study of RP101 for Metastatic Pancreatic Cancer
- Obesity Boosts Drug Spending; Mayo Clinic Study Says Extra Weight Increases Prescription Tab for Men
 |
 |
User Comments (0)
RSS Feeds